论文信息 - Sorafenib (SOR) plus docetaxel (DOC) as first-line therapy in patients with HER2-negative metastatic breast cancer (MBC): A randomized, placebo-controlled phase II trial. - 字舞流文

Sorafenib (SOR) plus docetaxel (DOC) as first-line therapy in patients with HER2-negative metastatic breast cancer (MBC): A randomized, placebo-controlled phase II trial.

M. Beckmann | A. Schneeweiss | F. Marmé | Marcus Schmidt | D. Strumberg | E. Grischke | B. Gerber | P. Klare | E. Solomayer | V. Moebus | F. Foerster | C. Windemuth-Kieselbach